The article focuses on the 5th Annual Cholangiocarcinoma (CCA) Summit, emphasizing advancements in systemic therapies, including chemotherapy, immunotherapy, and novel targets for cholangiocarcinoma and biliary track cancers. Topics include novel targets such as PRMT5, vascular endothelial growth factor (VEGF) and DLL4 dual blockade, BAP1, and immunotherapy combinations with existing approved treatments.